tbuckley/cabot-search huggingface dataset:
Liver disease as a risk factor for cognitive decline and dementia: An Under-recognized issue #
Authors: Julia L. Newton
Journal: Hepatology (2008)

We appreciate the very positive comments from Dr. Yilmaz and Dr. Ozdogan regarding our recently published article.1 We absolutely agree that further work is needed to explore the prevalence of cognitive impairment in other chronic liver diseases, particularly in the earliest (precirrhotic) stages of the disease. It is time to revisit the conventional view that cognitive problems in chronic liver disease are entirely due to hepatic encephalopathy. The potential risk factors for cognitive decline that Yilmaz and Ozdogan describe in those with nonalcoholic fatty liver disease (NAFLD) are all certainly plausible. We would also suggest that the relationship between autonomic dysfunction and cognitive decline highlighted in our recent article1 (and recognized in nonhepatic diseases) is an additional potential pathogenetic mechanism for cognitive impairment in NAFLD. We have recently presented work at the American Association for the Study of Liver Diseases confirming that autonomic dysfunction is as prevalent and severe in NAFLD as that seen in primary biliary cirrhosis.2 We therefore agree wholeheartedly that further studies are urgently needed to explore the prevalence and pathogenesis of cognitive dysfunction in those with all forms of chronic liver disease. Recognizing that symptoms related to cognitive impairment can affect not only those with end-stage liver disease is the first step to improving our understanding of this phenomenon, developing appropriate targeted treatments, and ultimately improving the quality of life of those with chronic liver disease. Julia L. Newton*, * Institute of Ageing and Health, Newcastle University, Newcastle, United Kingdom.
The LD50
Authors: John Jennings
Journal: JAMA (1985)

<h3>To the Editor.—</h3> In his recent letter to the editor, Dr Hubbard failed to cite important actions by the Pharmaceutical Manufacturers Association (PMA) to bring about change in use of the median lethal dose (LD<sup>50</sup>) test. Our position paper,<sup>1</sup>approved by the PMA Board of Directors in 1982, helped precipitate the Food and Drug Administration LD<sup>50</sup>Conference mentioned in Dr Hubbard's letter. It is the PMA's position that, although there is no adequate substitute for acute toxicity studies involving the use of laboratory animals, a review of the utility of the precise LD<sub>50</sub>test reveals that neither the toxicologist nor the clinical pharmacologist needs a<i>precise</i>LD<sub>50</sub>value. Carefully controlled and professionally performed acute experiments can be conducted that require fewer animals and yet are more meaningful and relevant to the introduction of therapeutic agents than the LD<sub>50</sub>test. Regulatory requirements should accommodate this
Abstract P346: Regulation of <i>GRK5</i> in Myocytes Is Mediated by Nuclear Transcription Factor [ê]B: A New Clue in Heart Disease
Authors: Kazi N Islam, Walter J Koch
Journal: Circulation Research (2011)

G protein coupled receptor kinase-5 (GRK5) plays a key role in the heart and it’s expression is increased in heart failure. Moreover, a human mutation within its amino-terminus appears to play a role in therapeutic responses to β-blockers in heart failure patients. Nuclear transcription factor kappa B (NF-κB), a ubiquitous transcription factor, is involved in the regulation of numerous genes in various tissues and activation of NF-κB has also been shown to be associated with heart disease. Here, we investigated the role of NF-κB signaling in the regulation of the GRK5 gene and GRK5 expression in neonatal rat ventricular myocytes (NRVMs). In analyzing the 5’-flanking DNA of GRK5 , the presence of a potential NF-κB binding site was observed in the promoter. Phorbol myristate acetate (PMA), a known stimulator of NF-κB, increased the levels of GRK5 in NRVMs. Conversely, treatment of NRVMs with N-acetyl cysteine (NAC), a known inhibitor of NF-κB, decreased the levels of GRK5 compared to control cells. Utilizing electrophoretic mobility shift assay (EMSA) with nuclear extracts from NRVMs treated with or without PMA, it was found that proteins bound to the GRK5 promoter containing the putative NF-κB binding site. When an antibody specific for NF-κB was utilized, a super-shift of the proteins binding to the putative NF-κB binding site was observed. Furthermore, interaction of NF-κB with GRK5 was confirmed by shift Western blot. Chromatin immunoprecipitation (ChIP) showed dynamic recruitment of both p50 and p65 to the NF-κB site of GRK5 promoter after treatment of NRVMs with PMA. Treatment of myocytes with siRNA and subsequent knock-down of NF-κB p65 decreased the levels of GRK5 as judged by real time quantitative PCR. Finally, adenovirus mediated overexpression of a dominant negative IκB-α in NRVMs inhibited the levels of GRK5. Taken together, our present studies suggest that NF-κB plays a potential role in the regulation of GRK5 transcription in myocytes and this may translate to key expressional changes seen in heart disease.
Multiple Human Exposures to a Rabid Bear Cub at a Petting Zoo and Barnwarming-- Iowa, August 1999
Journal: JAMA (1999)

On August 27, 1999, a black bear cub, approximately 5-6 months old, died after several hours of acute central nervous system symptoms; preliminary test results available on August 28 indicated the bear had rabies. The bear was part of the Swenson's Wild Midwest Exotic Petting Zoo in Clermont, Iowa (northeastern Iowa). At the petting zoo, visitors fed, wrestled, and may have been nipped by the bear. The bear also was taken to an August 14 barnwarming at the Tharp barn in Holy Cross, Iowa (eastern Iowa), where it reportedly nipped people. An estimated 400 people from 10 states (Arizona, California, Florida, Illinois, Iowa, Minnesota, New Mexico, New York, Ohio, and Wisconsin) and Australia had contact with the bear cub at either the petting zoo or the barnwarming during the 28 days before its death, during which the bear may have transmitted rabies virus.
In the Spotlight: Biomedical Signal Processing
Authors: Sergio Cerutti
Journal: IEEE Reviews in Biomedical Engineering (2012)

The author has taken the inspiration for drafting this short report from the Annual IEEE-EMBS Conference which was held in San Diego, CA, USA, last August. This conference is the most important event for being informed about the state of the art in Biomedical Engineering and for meeting the most distinguished experts in this area of research and the relevant applications. Again this year, the Theme of Biomedical Signal Processing scored among the most popular ones with more than 400 contributions. The great importance of this Theme has been confirmed by the excellent keynote speakers: many of them made reference to the importance of proper signal and data processing. It is argued that the basic challenge to realize a really successful tool for primary preventive medicine is to transfer (hopefully in an 'easy' fashion) to micro/nano scales the processing algorithms and devices, which were implemented and successfully tested in the last decades for diagnostic and therapeutic purposes. This statement serves as the author's opportunity to inform readers on the European Union vision for ICT Research Programs in the next years.
New, Further Attenuated Live Measles Vaccine Tested in 6,000 Children
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Lectures: DELIVERED IN ST. BARTHOLOMEW'S HOSPITAL, LONDON
Authors: F. C. Skey
Journal: BMJ (1856)

New with regard to food.If the infant be at the brest, keep him entirely to it.If he be weaned, and under two ars old, give him milk and water, and cold water to drink.If he be older, give him toast and water, and plain water from the pump, as much as he chooses; let it be quite cold-the colder the better.Weak black tea, or thin gruel, may be given, but caring little if he take nothing but cold water, unless he be an infant at the breast.Avoid broths and stimulants of every kind.Now, you must warily watch for a change of tempera- tre of the skin.As long as the skin is hot, the above plan I steadily follow; but the moment the skin of the patient becomes cool, which it will do, probably, in five or seven days, instantly close the window, and immediately put more clothes on the bed.But still do not purge.You will find the acidulated infusion of roses most grateful to the little patient; it will abate the fever, it will cleanse his tongue, it will clear his throat of mucus, it will, as soon as the fever is abated, give him an appetite.I believe, too, the acid treatment has some peculiar proper- ties of neutralising the scarlatina poisn.I do not pretend to explain how, or why, or wherefore.When the appetite returns, you may consider the patient to be safe.The diet must now be gradually improved.Bread and butter, milk and water, and arrow-root, made with equal parts of milk and water, may be given for the
Interaction Between MAO-A Genotype and Maltreatment in the Risk for Conduct Disorder: Failure to Confirm in Adolescent Patients
Authors: Susan Young
Journal: American Journal of Psychiatry (2006)

Objective: Childhood maltreatment is a potent risk factor for subsequent aggressive and criminal behavior. A recent study suggested that the relationship between maltreatment and antisocial behavior may be moderated by a genetic vulnerability conferred by a functional polymorphism in the MAO-A gene. The authors investigated whether these findings would generalize to a clinical cohort of adolescents, examining whether there was a stronger association between maltreatment and conduct disorder severity in patients carrying the low MAO-A activity allele. Method: Male adolescent patients (N=247) entering residential or intensive day treatment for persistent conduct and substance use problems were examined. Conduct disorder severity was indexed by a lifetime count of DSM–IV criteria obtained through structured psychiatric interviews. Maltreatment scores were derived from summing neglect and abuse events reported to have occurred before age 11. Results: Neglect, verbal/psychological abuse, physical abuse, and sexual abuse were prevalent among patients. Although level of maltreatment and lifetime conduct disorder symptoms were significantly correlated, no genetic-environmental interaction with genotype for maltreatment was found. Conclusion: The results of the current study do not support the hypothesis that a polymorphism in the gene encoding MAO-A contributes to the genetic risk for conduct disorder.
Immunotherapy with transfer factor
Authors: C. H. Kirkpatrick
Journal: JAMA (1977)

Several years ago, H. Sherwood Lawrence, MD, reported that it was possible to transfer delayed-type skin reactivity from sensitive human donors to unreactive recipients, with materials from disrupted blood leukocytes. This finding was in sharp contrast to the previous observations in guinea pigs in which there was an obligatory requirement for living lymphoid cells for achievement of passive transfer. The longevity of the passively acquired reactivity was also different. In guinea pigs, the transferred reactivities were lost within a few days unless inbred animals were used; in man, the state of hypersensitivity lasted for many months, even when allogeneic relationships existed between the donors and recipients. The component of the lysates that was responsible for this activity was designated "transfer factor." For several years, transfer factor rested as an immunologic curiosity. Little was known about its composition or mechanism of action. Attempts to investigate the phenomenon of transfer of delayed
The Baby's First Two Years.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients
Authors: P. Viens, C. Chabannon, P. Pouillard, M. Janvier, W. Brugger, J. Y. Blay, F. Oberling, R. Capdeville, C. Newman, V. Méresse, Z. X. Xu, E. Platzer, P. Van der Auwera, D. Maraninchi
Journal: Journal of Clinical Oncology (2002)

To evaluate the safety, pharmacokinetics, and efficacy of three different dose levels of pegylated granulocyte colony-stimulating factor (Ro 25-8315) on progenitor cell mobilization and hematologic recovery in cancer patients.Breast cancer patients (n = 36) were randomly assigned to receive before (part I) and after (part II) chemotherapy either a single-dose injection of Ro 25-8315 (20 microg/kg, n = 9; 60 microg/kg, n = 9; 100 microg/kg, n = 10) or a standard daily dose of filgrastim (part I, 10 microg/kg/d; part II, 5 microg/kg/d) (control group, n = 8).Overall, Ro 25-8315 was well tolerated. In part I, more progenitor cell mobilization was observed with Ro 25-8315 100 microg/kg. The peak of circulating CD34(+) cells was obtained at day +5 in the four groups, and the absolute neutrophil count (ANC) returned to less than 20 x 10(9)/L by day +15. In part II, high levels of circulating CD34(+) cells (> 20 cells/microL) were obtained in all four groups. The chemotherapy-induced neutropenia (< 1 x 10(9)/L) was similar in the four groups. Ro 25-8315 100 microg/kg was more effective than filgrastim in reducing the number of patients with an ANC less than 0.5 x 10(9)/L on day +12 after chemotherapy.A single injection of Ro 25-8315 100 microg/kg might be the optimal dose for steady-state peripheral-blood progenitor cell mobilization. A single injection of 20, 60, or 100 microg/kg could be as efficient as daily administration of filgrastim to correct chemotherapy-induced cytopenia. The optimal dose of Ro 25-8315 should be determined according to the planned chemotherapy regimen.
Books Received
Authors: Filipe Barbosa, Catarina Mota, Patrícia Patrício, Cristina Alcântara, Carlos Ferreira, António Barbosa, Marianne Heins, Hans Knoop, Gijs Bleijenberg, Tom Kindlon, Anna Bartak, Helene Andrea, Marieke D. Spreeuwenberg, Moniek Thunnissen, Uli M. Ziegler, Jack Dekker, Fleur Bouvy, Elisabeth F.M. Hamers, Alain Braillon, Anke M.M.A. Meerman, Theo Stijnen, Paul M.G. Emmelkamp, John S. Ogrodniczuk, Michel Leroy, Gwenolé Loas, Fernando Perez-Diaz, Fabrizio Schifano, Stefano D'Offizi, Michele Piccione, Ornella Corazza, Paolo Deluca, Zoe Davey, Giuditta Di Melchiorre, Lucia Di Furia, Magí Farré, Liv Flesland, Miia Mannonen, Aino Majava, Boudewijn Van Houdenhove, Patrick Luyten, Marco Chiesa, Rachel Sharp, Peter Fonagy, Stefan Priebe, Michelle Richardson, Maire Cooney, Oluwatoyin Adedeji, Rosemarie McCabe, Jan J.V. Busschbach, Roel Verheul, Stefania Pagani, Teuvo Peltoniemi, Holger Siemann, Arvid Skutle, Marta Torrens, Cinzia Pezzolesi, Peer van der Kreeft, Norbert Scherbaum, Julia Romanowska, Gerry Larsson, Maria Eriksson, Britt-Maj Wikström, Hugo Westerlund, Töres Theorell, Satz Mengensatzproduktion, Druck Reinhardt Druck Basel, Druck Reinhardt Druck Basel
Journal: Psychotherapy and Psychosomatics (2011)
Variations in Rate of Human Osteon Formation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE NETHERLANDS
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Publication Bias and the Editorial Process
Authors: Jeffrey L. Kaufman
Journal: JAMA (1992)

<h3>To the Editor.</h3> —The study by Dickersin et al from Johns Hopkins<sup>1</sup>on publication of research results and the Editorial by Dr Rennie and Ms Flanagin<sup>2</sup>neglected to analyze the response of journal editors to the reputation of the institution from which the manuscript originated. My experience is that editors are influenced favorably to publish manuscripts from "big name" institutions. I am concerned that "negative" results from a less prominent institution are less likely to be published, even if the paper is well written and the results are derived from an excellent protocol with impeccable numbers. What was the pattern of editorial response? How many manuscripts were returned for revision more than once? Were the reviews brief or "nitpicking"? How often did the Hopkins authors come away with the impression that the reviewer never read the manuscript beyond the abstract and that the review was unfair? Based on
Pseudoallergic Reactions to Nonsteroidal Anti-inflammatory Drugs
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rough Voice
Authors: E REES
Journal: BMJ (1964)

to the cells they infect.The transformation of cells grown in tissue culture by viruses or by chemical carcinogens4 opens up many new possibilities for research.Hopes are justifiably high that this approach will lead both to a new understanding of carcinogenic mechanisms and to new ways of preventing and possibly treating cancer.It seems, for instance, to be only a matter of time before a virus or group of viruses is found to be causing Burkitt's African lymphoma and methods